SAN DIEGO, CA – September 23, 2020 – Neurelis, Inc., announced today that it will be investigating the safety and pharmacokinetics of the company’s lead product, VALTOCO® (diazepam nasal spray), in children with epilepsy aged two to five. VALTOCO is currently available for adults and pediatric patients 6 years of age and older. This is […]
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.